Claim Ledger
50% answered
Did management answer the analysts?
12 analyst questions audited, 4 evaded or deflected.
View Claim Ledger →Cipla Ltd — Q4 FY24
Cipla reported Q4 FY24 revenue of INR 6,163 crore, up 10% YoY, with EBITDA margin expanding 95 bps to 21.4%.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Cipla reported Q4 FY24 revenue of INR 6,163 crore, up 10% YoY, with EBITDA margin expanding 95 bps to 21.4%. Full-year revenue hit a record INR 25,455 crore (+14% YoY) and PAT stood at INR 4,106 crore (16% margin). Growth was driven by One India crossing INR 10,000 crore, North America reaching $906 million (+24% YoY), and South Africa leading prescription market share. Key drivers included branded prescription growth (10% YoY), lanreotide market share of 20.8%, and albuterol share rising to 15.5% in April. Management guided FY25 EBITDA margin of 24.5%-25.5% (up to 100 bps expansion) and capex of INR 1,500 crore. Risks include USFDA observations at Patalganga and Kurkumbh facilities, potential disruption from trade generics channel restructuring, and timing uncertainty for Goa plant reinspection and Abraxane launch.
सिप्ला ने चौथी तिमाही में 6,163 करोड़ रुपये का कारोबार किया, जो पिछले साल से 10% ज्यादा है। कंपनी की कमाई पर खर्च घटाने के बाद बचत (EBITDA मार्जिन) 21.4% रही, जो पिछले साल से 0.95% बढ़ी। पूरे साल का कारोबार 25,455 करोड़ रुपये रहा, जो अब तक का सबसे ज्यादा है। मुनाफा (PAT) 4,106 करोड़ रुपये रहा। भारत में कारोबार 10,000 करोड़ पार कर गया, अमेरिका में 906 मिलियन डॉलर का कारोबार हुआ। दवाओं की बिक्री बढ़ी, खासकर लैनरियोटाइड और एल्ब्युटेरोल की। अगले साल कंपनी 24.5-25.5% तक मार्जिन और 1,500 करोड़ रुपये निवेश का लक्ष्य रखती है। जोखिमों में अमेरिकी स्वास्थ्य विभाग की जांच और कुछ फैक्ट्रियों में देरी शामिल है।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Risks
4 risks
Risk Intelligence
USFDA observations at Patalganga and Kurkumbh facilities
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
North America Annual Revenue
$906M
+24% YoY
All-time high annual revenue driven by differentiated portfolio and base business demand.
Lanreotide Market Share
20.8%
+? pp YoY
Scaled to 20.8% share in a benchmark 505(b)(2) market as of Feb 2024.
Albuterol Market Share (April 2024)
15.5%
+2.5pp vs Q4 exit
Increased from 12-13% at year-end to 15.5% in April 2024.
One India Revenue
INR 10,000Cr
+10% YoY
Crossed INR 10,000 crore threshold for FY24, led by branded prescription and trade generics.
What Changed vs Last Quarter
NEW
FY25 EBITDA margin guidance of 24.5%-25.5%
Management expects EBITDA margin expansion of up to 100 bps over FY24's 24.5%, driven by cost measures and portfolio mix.
NEW
Capex of INR 1,500 crore in FY25
Capital investments planned to enhance manufacturing capability and sustainability.
NEW
North America revenue growth aspiration for FY25
Aim to grow top line YoY, backed by commercial execution of existing portfolio and new launches.
NEW
Launch of 4 peptide assets in FY25
Targeting to launch four peptide assets during the fiscal year.
DROPPED
FY24 EBITDA margin at higher end of 23-24%
Full-year EBITDA margin trending at the higher end of the previously guided range of 23-24%.
DROPPED
Advair filing by mid-FY25
Advair generic expected to be filed by mid-FY25 from an alternate site, with approval likely by end of next fiscal.
DROPPED
Four peptide launches in FY25
Four peptide launches planned in FY25, with one asset awaiting approval expected in Q1 FY25.
DROPPED
Symbicort filing completed
Filed generic Symbicort and one other inhalation asset; second site transfer to be added before approval.
NEW RISK
USFDA observations at Patalganga and Kurkumbh facilities
Patalganga received six 483 observations and Kurkumbh one; official classification awaited, potentially delaying product approvals.
NEW RISK
Trade generics channel restructuring disruption
Transition to direct stockist model may cause temporary hiccups in Q1 FY25, impacting trade generics growth.
NEW RISK
Potential pricing pressure in Lanreotide market
As a two-player market, pricing may vary depending on competitor actions, though management aims to grow total value.
RISK GONE
US FDA warning letter at Indore facility
Indore facility received a warning letter citing Albuterol complaints; resolution timeline uncertain and may impact future approvals.
RISK GONE
US generic pricing compression
Pricing environment in US generics is in a downcycle; compression expected to move from 4-6% to 6-8% within a year.
RISK GONE
Abraxane launch delay
Abraxane launch via third-party transfer is taking longer; fastest route is from Goa facility, which is subject to FDA inspection.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24, Q3 FY24
Filed generic Symbicort and one other inhalation asset; second site transfer to be added before approval.
Mentioned in Q1 FY24, Q2 FY24, Q3 FY24
Indore facility received a warning letter citing Albuterol complaints; resolution timeline uncertain and may impact future approvals.
Mentioned in Q1 FY24, Q2 FY24
Albuterol share is dependent on which variant the market buys; recovery to prior highs is not fully in Cipla's control.
Mentioned in Q1 FY24, Q3 FY24
Goa facility due for re-inspection; delay or adverse outcome could further delay Abraxane launch.
Fast read
Guidance and risk preview
Management expects EBITDA margin expansion of up to 100 bps over FY24's 24.5%, driven by cost measures and portfolio mix.
Patalganga received six 483 observations and Kurkumbh one; official classification awaited, potentially delaying product approvals.
View Risks →